09.45 – 10:00
A closer look into the impact of a six months personalized combined lifestyle intervention on physical activity, heart rate, sleep and metabolic resilience
S. Wopereis (Leiden)

10.00 – 10:15
The association between ultra-processed food intake on body composition and metabolic parameters after a combined lifestyle intervention
K.A.M. Geurts (Rotterdam)

10.15 – 10:45
Objectively-determined chronoactivity and type 2 diabetes risk: a prospective study in UK Biobank participants
Q. Feng (Leiden)

10.30 – 10.45
Assessing the effect of an intensive lifestyle intervention on healthy and unhealthy behaviors in daily life for individuals with overweight and obesity
E. Vanbrabant & J. Hesen (Maastricht)

10.45 – 11.00
A real-world feasibility study for an e-health blended personalised lifestyle intervention to affect the risk of developing type 2 diabetes in people with prediabetes
L.G.P. Peters (Leiden)

09.45 – 10.00
Beta cell-specific 3’UTR modulation by genetic variants during type 2 diabetes reveals miRNA regulation of PTEN
T.J.J de Winter (Leiden)

10.00 – 10.15
Adipose stromal cell secretome for a sustainable microenvironment within a subcutaneous polymeric scaffold for insulin-producing cell transplantation
A.M. Smink (Groningen)

10.15 – 10.30
HNF4α Expression Differs Between Fetal and Adult Human Beta Cells
R.D. Hauck (Leiden)

10.30 – 10.45
Hypoxia-inducible pathway mitigates mitochondrial dysfunction in pancreatic β-cells
R. Fagundes Rosa (Leiden)

10.45 – 11.00
MAP3K15 variants and their role in in modulating diabetes risk: functional analyses and protective effects in knockout mice
D. Struik (Groningen)

11:00 – 11:15
Developing a vascularized islet-on-a-chip model
M.S. van Agen (Leiden)

09:45 – 10:00
Pharmacological inhibition of fructose metabolism reduces liver fat and improves insulin sensitivity in participants with MASLD
E.J.C. Koene (Maastricht)

10:00 – 10:15
Dynamic 3D Deuterium Metabolic Imaging in the liver at 7T
M.M. Konig (Utrecht)

10:15 – 10:30
Liver Fibrosis as a Predictor of Cardiovascular Risk in Patients with Severe Obesity: Insights from the Assisi Study
A. N. Saidi (Rotterdam)

10:30 – 10:45
Advanced MASLD Fibrosis: Low Number-Needed-to- Screen in multiple lines of care
S. Driessen (Amsterdam)

10:45 – 11:15
Opportunities for young researchers offered by Diabetes Fonds
Mariette Boon, Erasmus MC
Frieda van der Jagt, DiabetesFonds

09.45 – 10.00
Metformin intolerance multicenter Switch study from immediate release (IR) to extended release (ER) formulation
O.W.F. Natan (Utrecht)

10.00 – 10.15
Individual Albuminuria Lowering Effects of Dapagliflozin in Patients with Type 2 Diabetes: A Series of Decentralized N-of-1 Randomized Placebo-Controlled Trials
J.M. Beernink (Groningen)

10.15 – 10.30
Advancing Pregnancy Care for Women with Diabetes: A Prospective Registry Cohort in the Netherlands
V. Duwel (Amsterdam)

10.30 – 10.45
The Diabetes Body Project: Acute effects of an eating disorder prevention program for young women with type 1 diabetes: a multi-national randomized controlled trial
M.H.C.L. Hennekes (Amsterdam)

10.45 – 11.00
Impact of pharmacological and dietary modulation of fructose, glucose and saturated fatty acids on serum sex hormone-binding globulin levels in humans
H. Chen (Maastricht)

11:00 – 11:15
Implementation of Lifestyle in Standard Care for Type 2 Diabetes: A Qualitative Study
E.A.G. Hietbrink (Enschede)

11.45 – 12.00
A fibre-rich Dutch healthy diet to improve cardiovascular risk profile in people with type 2 diabetes: a randomized controlled trial
I. van Damme (Wageningen)

12.00 – 12.15
Exploring fructose kinetics in Type 2 Diabetes: preliminary data of 20 ERIE-trial participants
F.H.M. Westerbeke (Amsterdam)

12:15 – 12:30
The effect of extended personalization to a combined lifestyle intervention program in Dutch primary care
D.J. Smid (Leiden)

12.30 – 12.45
The association between ultra processed food intake and stress and eating behaviour in a combined lifestyle intervention
R.E.H. Meeusen (Rotterdam)

12.45 – 13.00
A fasting-mimicking diet programme reduces liver fat and inflammation/fibrosis measured by MRI-derived biomarkers in patients with type 2 diabetes
E. van den Burg (Leiden)

13.00 – 13.15
Feasibility of following a fasting-mimicking diet program in persons with type 2 diabetes in primary care – a mixed methods study
M.P. Schoonakker (Leiden)

11.45 – 12.00
Cannabidiolic acid mitigates postpartum development of metabolic dysfunction-associated steatotic liver disease in a mouse model of gestational diabetes mellitus
J.K.Kruit (Groningen)

12.00 – 12.15
Glycodeoxycholic acid inhibits primary bile acid synthesis with minor effects on glucose- and lipid homeostasis in humans
E.C.E. Meessen (Amsterdam)

12.15 – 12.30
Fetuin B-related changes in adipose tissue transcriptome and plasma proteome are related to metabolic and insulin signaling
R.C.R. Meex (Maastricht)

12.30 – 12.45
Impact of Elevated Branched-Chain Amino Acid Levels on Insulin Signaling and Metabolic
F. Vanweert (Maastricht)

12.45 – 13.00
Myokine secretion and metabolic pathways under resting and contractile conditions in primary human myotubes: a matter of oxygen?
L. Mennens (Hasselt/Maastricht)

13.00 – 13.15
Different risks of type 2 diabetes between subtypes of insulin resistance
J. van der Velde (Leiden)

11.45 – 12.00
Methylglyoxal has no direct effect on immune cell recruitment or activation but is involved in trained immunity
K. Wouters (Maastricht)

12.00 – 12.15
Unraveling the Impact of Daily Life Stress on Glucocorticoid Regulation and Cardiovascular Disease
M. Boon (Rotterdam)

12.15 – 12.30
Hypoglycaemia levels of adrenaline elicit an inflammatory response in people with or without T1DM
I.F. Mustafajev (Nijmegen)

12.30 – 12.45
A single experimental hypoglycaemic event induces acute and prolonged transcriptional changes in circulating monocytes of people with type 1 diabetes and healthy controls
M.S. Hendriksz (Nijmegen)

12.45 – 13.00
Hair glucocorticoid levels and the metabolic syndrome: a role for age?
S. Kuckuck (Rotterdam)

13.00 – 13.15
Obesity affects the adipocyte glycosylation machinery and N-glycan profiles in mice
Z.Q. Zhang (Leiden)

11.45 – 12.00
MASLD and metALD: the number of cardiometabolic risk factors and the amount of liver fat in relation to the risk of type 2 diabetes and cardiovascular disease
J. van der Velde (Leiden)

12.00 – 12.15
A clinical dose of adipose-derived stem cells does not significantly affect atherosclerotic plaque in a streptozotocin-induced hyperglycaemia mouse model
A. Korn (Amsterdam)

12.15 – 12.30
The role of perivascular adipose tissue in the regulation of microvascular function in a mouse model of prediabetes
E. D’Alessandro (Maastricht)

12.30 – 12.45
Association of Arterial Stiffness with Whole-body and Tissue-specific Insulin Resistance and with Incident Diabetes: The Maastricht Study
J. Shen (Maastricht)

12.45 – 13.00
Associations of blood pressure with retinal arteriolar narrowing and urinary albumin excretion are modified by prediabetes and diabetes: The Maastricht Study
K. Wang (Maastricht)

11.45 – 12.00
In-depth pressure analysis of indoor versus regular custom-made footwear for people with diabetes and peripheral neuropathy
L.E. Vossen (Amsterdam)

12.00 – 12.15
Peak Plantar Pressure as a Prognostic Marker in Charcot Neuro-Osteoarthropathy
V.E.L. Milbourn (Amsterdam)

12.15 – 12.30
Exploring unknowns in footwear design for individuals with diabetes at moderate-to-high risk of ulceration: a knowledge gap analysis
I. Gigante (Amsterdam)

12.30 – 12.45
Reliability of a measurement protocol to obtain plantar pressure data in neuropathic diabetic patients using the FootWork Pro® Platform
D.J.J. van Gulick, (Amsterdam)

12.45 – 13.00
The effect of using a bone biopsy guided antibacterial therapy on remission of diabetic foot osteomyelitis: A randomized controlled trial
R.S. Lagrand (Amsterdam)

13.00 – 13.15
Quantifying Mechanical and Morphological Properties of Plantar Foot Soft Tissues: A Systematic Review of Methods and their Clinimetric Properties
A. Vicentini (Amsterdam)

09.00 – 09.15
Using an in vitro large intestine model to identify fiber(s) able to induce a fermentation switch in the gut microbiota of individuals with obesity
T. van Deuren (Maastricht)

09.15 – 09.30
β-hydroxybutyrate Alters Cell Composition and Gives Rise to Bihormonal Cells in Human Pancreatic Islets
Y.S Chae (Leiden)

09:30 – 09:45
From Disruption to Recovery: Antibiotics, Dietary Fiber, and the Fate of Bacterial Membrane Vesicles in Human Metabolic Health
J. Verbunt (Maastricht)

09:45 – 10:00
Encapsulated autologous faecal microbiota transplantation may halt beta cell function decline in recently diagnosed type 1 diabetes mellitus in a single-arm trail
P. de Groen (Amsterdam)

10.00 – 10.15
Lactobacillus delbrueckii is associated with methylglyoxal levels in type 2 diabetes
O.I. Akinrimisi (Amsterdam)

09.00 – 09.15
SAF is associated with glucose variability measured by continuous glucose monitoring – The Maastricht Study
N. Dimitropoulou (Maastricht)

09.15 – 09.30
How variable is the glycemic variability: analysis of CGM data over one year
E. Schupp (Nijmegen)

09:30 – 09:45
HbA1c Variability Score as a predictor for complications and mortality in patients with type 2 diabetes
S.E.M. Teunissen (Almelo)

09:45 – 10:00
Effect of Continuous Glucose Monitoring on Glycemic Control in Adults with Type 2 Diabetes
M. Jancev (Utrecht)

S.E.M. Teunissen (Almelo)

09:45 – 10:00
Effect of Continuous Glucose Monitoring on Glycemic Control in Adults with Type 2 Diabetes
M. Jancev (Utrecht)

10:00 – 10:30
Opportunities for young researchers offered by Diabetes Fonds
Marleen Kunneman, LUMC
Roel Nahuis, DiabetesFonds

09.00 – 09.15
Cardiometabolic effects of the FGF-system in T2DM: studies in the postprandial state
L.A.M. Konings (Rotterdam)

09.15 – 09.30
Hepatic fibrosis determines cardiovascular risk in T2DM independent from other cardiovascular risk factors: Report from the AleCardio Trial
W.W. XU (Utrecht)

09:30 – 09:45
The food matrix affects systemic fructose dynamics and diastolic blood pressure: results from an open label, randomized, crossover study
M.A.J. van Oeteren (Maastricht)

09:45 – 10:00
Increased risk of incident stroke in people with type 2 diabetes is not mediated by microvascular dysfunction: pooled analysis of three population-based studies
I.L.M Steens (Maastricht)

10.00 – 10.15
Steatotic liver disease interacts with a polygenic risk score for VLDL clearance on hypertriglyceridemia risk: The Maastricht Study
Z. Ren (Maastricht)

09.00 – 09.15
Assessment of a 14-Week diabetes rehabilitation program for individuals struggling to attain target HbA1c despite advanced therapies: A prospective cohort study investigating glycemic control and psychosocial outcomes
A. Kooistra (Groningen)

09.15 – 09.30
Experienced blood glucose regulation after menopause: a cross-sectional survey in women with type 1 diabetes
E.M. Speksnijder (Amsterdam)

09:30 – 09:45
Metabolic and functional improvements 3 months after total knee replacement surgery
J. Most (Heerlen)

09:45 – 10:00
Comparison of glycemic responses following meal tolerance testing during early and late second trimester with oral glucose tolerance in overweight pregnant women
P. Arum (Groningen)

09.00 – 09.15
Psychological health of people with type 1 diabetes, referred for pancreas or islet transplantation
S.D. Huisman (Leiden)

09.15 – 09.30
Beta cell mass as quantified by exendin PET/CT imaging is similar in individuals with and without remission of type 2 diabetes after Roux-en-Y Gastric Bypass
S. Tokgöz (Nijmegen)

09:30 – 09:45
Clinically compliant differentiation of human pluripotent stem cells into beta cells and enrichment of stem cell islets
B. Rajaei (Leiden)

09:45 – 10:00
Islets from older organ donors and the effect on transplantation outcome
E.J. Hammink (Leiden)

10.00 – 10.15
Improvement in Glycemic Control and Elimination of Exogenous Insulin Use in Patients with Type 1 Diabetes Infused with Fully Differentiated Islet Cells (VX-880)
E.J.P. de Koning (Leiden)